CalciMedica Inc
NASDAQ:CALC
Net Margin
CalciMedica Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
CalciMedica Inc
NASDAQ:CALC
|
39m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
672.1B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
430.4B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.8B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.1B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
216.6B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.3B USD |
17%
|
CalciMedica Inc
Glance View
CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. The firm is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CalciMedica Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet